a&r research capital

A&R Research Capital

The Quantitative Fund

About a&r

Since we begun, our purpose has been to become your innovation experts in natural health products.

Within the consumer health care space, a&r is one of the leading consultancy and clinical research providers with a strong focus on natural health products. 

For over two decades, we have supported our clients with scientific, regulatory, and clinical expertise.

With experience, enthusiasm, and a robust result-oriented approach, we apply our core competences: the compilation of dossiers for market compliance in Europe and the performance of clinical studies according to local and international requirements.

We help our customers with the design and implementation of future-oriented innovation strategies within their target markets.

OUR MANAGEMENT TEAM

DR. VOLKER SCHEHLMANN

Managing Director

DR. HEIKE STIER

Head of Consulting and Strategic Innovation

ANNE GENSCH

Head of Clinical Operations

DIPL. MED. LIANA VISMANE

Head of Study Center

DR. GORDANA BOTHE

Head of Scientific Affairs

Our Experience

In 2001, analyze & realize was founded by the physician Christof Jaenicke and botanist Dr. Joerg Gruenwald, emerging from their previous independent consulting firms. Human clinical trials have been conducted in our study center since the inception of our company.

At first, medicinal consulting with regards to herbal medicinal substances was the main focus, specifically the compilation of CTDs for traditional herbal medicinal products. Later, consulting was very successfully expanded towards functional foods, food supplements, food for special medical purposes, and medical devices. In particular, our vast expertise in the areas of Health Claims and Novel Food makes a&r one of the leading consultancies in the EU.

Get in touch with us

We would love to hear from you. Here is how you can reach us:

Salutation Salutation Mrs Mr Dr Prof

First name *

Phone number

Subject* Subject* Supplements Herbal drugs Substance based medical devices Marketability of innovative ingredients Product specific claims Other*

How did you hear about us? How did you hear about us? Flyer Website Google LinkedIn Other*

Other Subject

Where did you here about us?

In case you do not wish to receive further information regarding new web and service offers by analyze & realize GmbH, you can object to this usage at any time. These e-mails are sent out in accordance with our data privacy statement: https://www.a-r.com/data-protection/. To object, please contact our data protection officer at [email protected]. Exercising your right to object incurs no further costs save the usual telecommunication costs. In case you do not wish to receive further information regarding new web and service offers by analyze & realize GmbH, you can object to this usage at any time. These e-mails are sent out in accordance with our data privacy statement: https://www.a-r.com/data-protection/. To object, please contact our data protection officer at [email protected]. Exercising your right to object incurs no further costs save the usual telecommunication costs. I've read and accept the conditions above.

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds Rates
• Top Mutual Funds
• Options: Highest Open Interest
• Options: Highest Implied Volatility
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive

Financial Services

• Industrials
• Real Estate
• Stock Comparison
• Advanced Chart
• Currency Converter
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Credit Card Offers
• Best Free Checking
• Student Loans
• Personal Loans
• Car insurance
• Mortgage Refinancing
• Mortgage Calculator
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Financial Freestyle
• Capitol Gains
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Ares capital corporation (arcc).

• Previous Close 20.97
• Bid 21.04 x 400
• Ask 21.10 x 900
• Day's Range 20.91 - 21.14
• 52 Week Range 18.55 - 21.84
• Volume 2,120,590
• Avg. Volume 3,243,371
• Market Cap (intraday) 13.289B
• Beta (5Y Monthly) 1.05
• PE Ratio (TTM) 7.37
• EPS (TTM) 2.86
• Earnings Date Oct 22, 2024 - Oct 28, 2024
• Forward Dividend & Yield 1.92 (9.16%)
• Ex-Dividend Date Sep 13, 2024
• 1y Target Est 22.12

Ares Capital Corporation Overview Asset Management / Financial Services

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full Time Employees

December 31

Fiscal Year Ends

Asset Management

Recent News: ARCC

Performance overview: arcc.

Trailing total returns as of 8/27/2024, which may include dividends or other distributions. Benchmark is S&P 500 .

1-Year Return

3-year return, 5-year return, compare to: arcc.

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ARCC

Valuation measures.

Enterprise Value

Trailing P/E

Forward P/E

PEG Ratio (5yr expected)

Price/Sales (ttm)

Price/Book (mrq)

Enterprise Value/Revenue

Enterprise Value/EBITDA

Financial Highlights

Profitability and income statement.

Profit Margin

Return on Assets (ttm)

Return on Equity (ttm)

Revenue (ttm)

Net Income Avi to Common (ttm)

Diluted EPS (ttm)

Balance Sheet and Cash Flow

Total Cash (mrq)

Total Debt/Equity (mrq)

Levered Free Cash Flow (ttm)

Research Analysis: ARCC

People also watch.

Fed's actions spoke louder than words in inflation fight, research shows

• Medium Text

EARNING PUBLIC TRUST

Sign up here.

Reporting by Howard Schneider; Editing by Paul Simao

Our Standards: The Thomson Reuters Trust Principles. , opens new tab

Thomson Reuters

Covers the U.S. Federal Reserve, monetary policy and the economy, a graduate of the University of Maryland and Johns Hopkins University with previous experience as a foreign correspondent, economics reporter and on the local staff of the Washington Post.

Australia consumer price inflation slows to 4-month low in July

Australian consumer prices rose at the slowest pace in four months in July as government rebates on electricity provided a temporary drag, while core inflation dipped to its lowest in six months in a sign costs were gradually cooling.

Ares Capital Corporation (ARCC)

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaura... [Read more]

Financial Performance

In 2023, Ares Capital's revenue was $2.61 billion, an increase of 24.71% compared to the previous year's $2.10 billion. Earnings were $1.52 billion, an increase of 153.67%.

Analyst Forecast

According to 8 analysts, the average rating for ARCC stock is "Buy." The 12-month stock price forecast is $21.63, which is an increase of 2.61% from the latest price.

• Press Press Releases
• Conversation

How To Allocate $100,000 In A Dividend Portfolio: A Strategic Guide For Income And Growth

I will demonstrate how you could allocate the amount of $100,000 by following the current composition of The Dividend Income Accelerator Portfolio, effectively balancing dividend income and dividend g...

My Top 10 High Dividend Yield Companies For August 2024

Today, I will present you with 10 dividend income-producing companies to consider investing in during this month of August. Each carefully selected company pays an attractive dividend, holds potential...

Rose's Income Garden Portfolio Review: 6.3% Yield And Winners For 3 Metrics

Rose's Income Garden has been active for 2.75 years with 85 stocks and a current yield of 6.3%. RIG has a total return of 12.08% YTD, outperforming SPY by 6.77% since inception on November 22, 2021. E...

Ares Capital Vs. Oaktree Specialty: Only One Is A Buy

ARCC is a blue-chip BDC with an extremely impressive track record. OCSL has a choppier track record but is managed by one of the most reputable credit investors, Oaktree. We compare them side-by-side ...

Ares Capital: Why Investors Should Be Wary Of Rising Recession Risks

Ares Capital's business model focuses on lending to small- and medium-sized enterprises, with investments mainly in senior secured notes and diversified sector exposure. Despite the rising interest ra...

52 Maybe Buy And Hold Stocks From August Dogcatcher Research

Screening for mid to large-caps, high (>2%) dividends, attractive or neutral rated, >5yr dividend history, positive cash flow stocks as of 8/12/24 data from YCharts revealed 52 potential buy to hold c...

2 BDCs That Will Likely Fare Better In A Recession

Despite recession fears, I plan to hold Business Development Companies due to their strong fundamentals despite being considered riskier investments. Unemployment has risen, fueling recession fears, b...

My Favorite Recession BDC: Ares Capital

Knowing who can give you what you need most, regardless of market conditions, is a must for retirees. ARCC has a stellar track record and shows no signs of fumbling the ball. You need income. The midd...

Ares Capital: A Top BDC For Turbulent Times

Ares Capital reported strong Q2 results, with a growing portfolio value and surging new investment commitments. Asset quality remained high and dividend coverage remained very decent as well. Despite ...

Ares Capital: Fees And Diversification Drive Strong Q2

ARCC delivered a solid 2.9% total NAV return over the quarter. It trades at a 9.2% dividend yield and 11.7% core earnings yield. Portfolio sector allocation includes software and healthcare, with a fo...

Building A $100,000 Dividend Portfolio With 3 ETFs And 3 Stocks

Times of higher uncertainty and elevated market volatility can provide investors with excellent opportunities to start building a dividend portfolio. The dividend portfolio I will present in today's a...

Dividend Harvesting Portfolio Week 179: $17,900 Allocated, $1,638.21 In Projected Dividends

The market experienced volatility due to big tech earnings, Fed meeting, and rising unemployment, leading to S&P and Nasdaq declines. Dividend Harvesting Portfolio profitability only retraced by 0.81%...

Big Dividends From A Recession-Resistant Portfolio

There are growing risks of a recession hitting due to weakening job numbers, rising unemployment, and weakening consumer spending capacity. We share a portfolio of high-yield stocks that should be abl...

Been Waiting For The Dip? 2 BDCs Worthy Of Nibbling On Here

BDCs are experiencing a pullback in share prices due to recession fears as well as investor sentiment, creating buying opportunities for investors. Blackstone Secured Lending and Ares Capital are two ...

Very Bad News For BDCs

The BDC sector is now in a correction. It also faces numerous significant headwinds. We share our outlook on and approach to the sector moving forward.

Ares Capital: The Pros And Cons After Q2 FY24 Results (Rating Upgrade)

As the signs indicated last quarter, investment activity has been strong. However, on a run-rate basis, I believe it is slowing down in Q3 FY24. As expected, Ares Capital's yields seem to be peaking. ...

Ares Capital: Recent Quarter Further Signifies Why They're A Must-Own BDC

Ares Capital is a must-own for income investors and their strong Q2 earnings further signified this. Company saw significant growth in net investment income, deal flow, and their portfolio value from ...

Bashing Big Yielders

Dividends need to be sustained to create value. We're highlighting a company that regularly falls short. I made some mistakes many years ago and I want to address them so we can all learn from them.

Ares Capital: As The Company And Industry Grow, So Do The Risks

Private credit has grown over the past five years, more than doubling industry AUM and creating new challenges for asset managers. Ares Capital (ARCC) is the largest business development company by ma...

Ares Capital's 9.0% Yield Is A No-Brainer

Ares Capital showed strong net investment income results for 2Q24, covering its dividend payout with a 4% improvement in dividend margin of safety. The company's portfolio focused on First Liens, with...

Ares Capital Is Still Dirt Cheap With Highly Attractive Yields

Ares Capital is a leading BDC that focuses on direct lending for the middle market. It benefits from market leadership and scale. ARCC posted a solid Q2 earnings release, justifying the market's optim...

Ares Capital: Investment Activity Leads To 9% Yields, Increased EPS

Ares Capital (ARCC) delivered a strong Q2, beating revenue and EPS expectations, and setting up a promising future for income investors. ARCC is well-positioned to benefit from a lower-rate environmen...

Ares Capital Q2 Earnings: Buy, Sell, Or Hold?

ARCC recently reported Q2 results. We highlight some of the things that the company is doing well. There are some meaningful headwinds forming for Ares Capital.

Ares Capital Corporation (ARCC) Q2 2024 Earnings Call Transcript

Ares Capital Corporation (NASDAQ:ARCC) Q2 2024 Earnings Conference Call July 30, 2024 10:00 AM ET Company Participants John Stilmar - Partner, Co-Head of Public Markets IR Kipp DeVeer - CEO Scott Lem...

Ares Capital Corporation Announces June 30, 2024 Financial Results and Declares Third Quarter 2024 Dividend of $0.48 Per Share

NEW YORK--(BUSINESS WIRE)--Ares Capital Corporation (“Ares Capital”) (NASDAQ: ARCC) announced that its Board of Directors has declared a third quarter 2024 dividend of $0.48 per share. The third quart...

What Is Research and Development (R&D)?

• R&D investment is crucial for high-growth companies, driving innovation and competitive advantage.
• Alphabet's 20% rule showcases a successful R&D strategy, leading to products like Gmail.
• Investors should monitor R&D expenses since they can indicate the potential for future growth and profits.
• Motley Fool Issues Rare “All In” Buy Alert

Research and development activities, known as R&D, are centered on discovering and creating new products or services for a company. Most companies have R&D expenses, but technology and pharmaceutical companies tend to spend especially large amounts to stay ahead of the competition. A major advantage of R&D expenses is their ability to be used to reduce taxes.

If you want to invest in high-growth companies, you'll need to understand how R&D works, the common types of R&D, and its importance to investors.

What is it?

What is r&d.

Governments and corporations incur R&D expenses. Corporations typically invest the funds in a more focused way, with a targeted return on investment (ROI) ; governments create grants and other ways for third parties to receive tax dollars for R&D. We'll focus more on the corporate side of things.

R&D is necessarily a long-term, focused expense. The types of products and services created in R&D departments often take years to develop. Corporations must balance the long time frame in R&D with the prospects of generating a positive ROI from the expenditure.

Measuring ROI is common for capital expenditures, such as buying new equipment or building a new office, but less common for operating expenses. With capital expenditures, the calculation is easy: You figure out how much cash flow you'll generate from the new investment and make sure the cash outflow is offset by the new profits.

With R&D, it's not quite as clear since some or most of the funds you invest will almost certainly be worthless. To paraphrase Thomas Edison, you don't fail; you just find thousands of things that don't work.

Alphabet 's ( GOOG -0.92% )( GOOGL -0.89% ) 20% rule is a good example of using R&D to maximize profits. All Google employees are allowed to work on personal projects one day a week. Products as diverse as Google News, Wear OS, and Gmail came from Alphabet's 20% rule. The R&D expense was obviously profitable for the company, but there was no way for Alphabet to determine the potential returns.

A good rule of thumb for corporations is the use of return on research capital, which is calculated by dividing the previous year's R&D by the current year's gross profit . The formula isn't perfect, but it's a widely accepted method of calculating ROI for R&D.

Types of R&D

Research and development trickles down into everyday products through several different models. Let's go over the most popular.

Corporate departments

Large corporations have departments staffed with engineers and industrial scientists who do research on various levels of the R&D process to develop new products and improve existing ones. The most common example is pharmaceutical companies developing and testing new drugs.

Start-ups and incubators

While large corporations may dedicate a department to R&D, some start-ups dedicate the whole company to R&D. For instance, companies with no revenue might spend all their money and time on developing self-driving cars, new cancer drugs , or even a better razor.

R&D-focused start-ups often work with incubators or accelerators. Both are run by venture capital firms and work with start-ups at different stages of the business.

Typically, incubators work with start-ups that are mostly still an idea. They help the company develop the idea, plan a business model, and create a product. Accelerators work with start-ups with an established product and help them bring the product to market and scale the business. The end game for both types is often a merger with a bigger company.

Mergers and acquisitions

The problem with R&D at a big corporation is that it's R&D at a big corporation. It's hard to be innovative when you work a 9-to-5 job, report to a middle manager, and get an annual 2% cost-of-living raise. So, when big corporate R&D departments aren't cutting it, the big corporation will often look to acquire a small, innovative company.

This process is more common than you'd think. The Android OS was originally developed by a start-up acquired by Google to get into mobile. Microsoft ( MSFT 0.09% ) acquired Hotmail and 86-DOS. eBay ( EBAY 0.63% ) acquired PayPal ( PYPL -0.62% ) and then spun it off. Google acquired YouTube. Disney ( DIS -0.96% ) acquired Pixar, ABC, ESPN, and Lucasfilm.

In addition to being a last resort for bigger companies that haven't been able to develop their own products, mergers and acquisitions (M&A) offer a much clearer ROI proposition. The corporation knows the exact amount it must spend to acquire the company and then can determine the cash flows from the acquisition once it's complete.

Its importance

Why is r&d important.

R&D is a vital expense for companies to continue growing and fending off competitors. Here are a few key reasons for a company to keep healthy R&D expenses going:

Competitive advantage

Developing strong competitive advantages is key to long-term profitability. This means constantly developing newer and better products that cost less to produce. Some of the biggest R&D spenders in the U.S. are companies such as Alphabet, Meta ( META -0.39% ), Microsoft, and Apple ( AAPL 0.37% ), which spend billions on R&D each year.

Let's look at Amazon ( AMZN -1.36% ) and the now-defunct Borders, both once flourishing general interest bookstores and almost direct competitors. Consider what the two bookstores look like now for someone who invested in them 25 years ago.

Amazon began as an online bookstore but now houses a multibillion-dollar cloud services business. It has profitable funnels to its Prime program, using tablets, e-readers, original TV series and movies, digital media players, and e-book subscription services. It also has voice-activated products, like Alexa, that wouldn't have existed if it hadn't invested in R&D over the past two decades.

Borders, meanwhile, has been out of business for a decade. A big reason Amazon still exists, and Borders doesn't, is that Amazon leveraged its R&D program.

Productivity advantages

R&D isn't focused only on developing new products. There is also substantial investment that goes into determining better ways to produce existing products. The faster and cheaper you can churn out widgets, the more money you'll make from each one -- and the less you can eventually charge for them, earning a competitive advantage .

New revenue sources

Every product has a life cycle. While some stay in the growth phase longer than others, there will eventually be an end to outsize profits. This is especially true for the pharmaceutical industry .

Companies spend billions developing and improving drugs, which then have a finite life cycle until the recipe is made available for everyone else to reproduce. If pharma companies weren't constantly investing in R&D, they would eventually run out of revenue sources.

Tax advantages

In addition to writing off R&D expenses on the income statement, many jurisdictions offer tax benefits for engaging in specific types of R&D.

Related investing topics

How to research stocks.

Good research can help investors find the best companies to invest in.

What to Invest in: Use Your Money to Make Money

Investing can be the most surefire path to becoming and remaining financially free. Here's how to get started the right way.

How to Invest in Bonds: A Beginner's Guide to Buying Bonds

Bonds are often considered a "safe" investment, but are they right for you?

How to Automate Your Investments

Putting your investments on autopilot can mean you save more. Follow these steps to get started.

A key to investment returns

R&D can be the lifeblood of a technology business . There is no better way to stay ahead of peers and create new opportunities for growth than research and development. If you're learning about investing in high-growth companies, keep an eye on the R&D line item. Make sure the company is investing enough and generating a satisfactory return on its investment.

Invest Smarter with The Motley Fool

Join over half a million premium members receiving….

• New Stock Picks Each Month
• Detailed Analysis of Companies
• Model Portfolios
• Live Streaming During Market Hours
• And Much More

Motley Fool Investing Philosophy

• #1 Buy 25+ Companies
• #2 Hold Stocks for 5+ Years
• #3 Add New Savings Regularly
• #4 Hold Through Market Volatility
• #5 Let Winners Run
• #6 Target Long-Term Returns

Why do we invest this way? Learn More

Related Articles

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/27/2024.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

3D Printing

Israel innovation.

• Circular Economy
• Cybersecurity and Data Privacy
• Digital Payments Economy
• Environmental Impact
• Global Sustainable Infrastructure
• Sustainable Future of Food
• USA Environmental Impact
• Active Bitcoin Futures
• Active On-Chain Bitcoin Futures
• Blockchain and Digital Economy Innovation
• Active Bitcoin Ethereum Futures
• Active Ethereum Futures

Cryptocurrency

Cryptoasset, why innovation.

• ARK offers three reason why we believe innovation should be represented in an investor’s portfolio:

Today, ARK identifies five major innovation platforms evolving at the same time and transforming industries.

ARK focuses on innovation so that our investors can capitalize on four market inefficiencies.

ARK believes innovation will change the way the world works and lead to a more sustainable future.

• The ARK Difference
• Investment Process
• Work at ARK
• Board of Directors
• Corporate Responsibility
• ARK Swag Store
• Investing in innovation starts with understanding it. Visit

Platforms Of Innovation: How Converging Technologies Should Propel A Step Change In Economic Growth

In this white paper, we examine the economic impact of converging technologies and explore how five converging platforms are likely to define this technological era.

We Invest Solely In Disruptive Innovation

For investors seeking long-term growth.

Investment Strategies

ARK’s thematic investment strategies span market capitalizations, sectors, and geographies to focus on companies that we expect to be the leaders, enablers, and beneficiaries of disruptive innovation. ARK’s strategies aim to deliver long-term growth with low correlation to traditional investment strategies and are offered in a variety of vehicles.

ARK Venture

Aims to provide broad exposure to disruptive innovation in both the private and public markets. ARK believes innovations centered around artificial intelligence, robotics, energy storage, DNA sequencing, and blockchain technology will change the way the world works and deliver outsized growth as industries transform.

ARK believes public blockchains are powering novel forms of coordination across finance and the internet. The Investment Manager believes that cryptocurrency value and market share dynamics will be “power law distributed,” meaning that a few cryptocurrencies will capture the majority of value.

ARK believes cryptocurrencies governed by open source networks are enabling a new paradigm for monetary systems and mechanisms to store and transfer value. The Investment Manager believes that cryptocurrency value and market share dynamics will be “power law distributed,” meaning that a few cryptocurrencies will capture the majority of value.

ARK Disruptive Innovation

Aims to provide broad exposure to disruptive innovation. ARK believes innovations centered around artificial intelligence, robotics, energy storage, DNA sequencing, and blockchain technology will change the way the world works and deliver outsized growth as industries transform.

Autonomous Tech & Robotics

Seeks to provide exposure to autonomous mobility, electric vehicles, robotics and automation, 3D printing, and space exploration. Advancements in these areas are enhancing productivity while reducing costs and transforming manufacturing, production, and infrastructure.

Genomic Revolution

Aims to provide exposure to DNA sequencing technology, gene editing, CRISPR, therapeutics, agricultural biology, and molecular diagnostics. These innovations can help in restructuring health care, agriculture, pharmaceuticals, and enhancing the quality of life.

Next Generation Internet

Seeks to provide exposure to artificial intelligence, deep learning, big data, cloud computing, cybersecurity, and blockchain technology. These innovations are changing the way the world manages information, analyzes data, purchases and consumes goods, and communicates across the globe.

ARK Early Stage Disruptors

Aims to provide broad exposure to early-stage disruptors in the public markets. ARK believes at the forefront of the innovation wave are “early-stage disruptors”— either newer public companies or companies that introduced new technologically-enabled products or services that are in the early stages of development.

Fintech Innovation

Aims to provide exposure to fintech innovations including mobile payments, digital wallets, peer-to-peer lending, blockchain technology, and financial risk transformation. These innovations should revolutionize the financial industry, impacting every sector of the global economy.

Space Exploration

Seeks to provide exposure to companies involved in space-related businesses like reusable rockets, satellites, drones, and other orbital and sub-orbital aircrafts. These innovations should transform logistics, observation, agriculture, telecom, drones, and may even put humans on Mars.

Mobility-as-a-Service

Aims to provide exposure to companies involved in self-driving vehicles, electric vehicles, autonomous ridesharing platforms, and aerial drones. These innovations should spur a transformative boost in economic productivity and subsume the traditional automotive industry.

Seeks to provide targeted exposure to companies in the 3D printing ecosystem, including 3D printing hardware, software, measurement, and materials. 3D printing should transform manufacturing by providing greater design complexity, accuracy, efficiency, and customization.

Aims to provide targeted exposure to Israeli companies at the forefront of innovation across health care, manufacturing, communications, and information technology. These companies are working to enhance many sectors of the global economy.

Invest In The Future Today

ARK identifies more innovation evolving today than ever before. We believe it is changing lives and businesses across the globe dramatically, creating opportunities to own the next big thing by investing in the future today.

Take Advantage Of Market Inefficiencies

The full magnitude of innovation and the opportunities it creates often are unrecognized or misunderstood by traditional investors. ARK focuses on innovation seeking to capitalize on four market inefficiencies.

Make The World A Better Place

ARK believes innovation creates simplicity and accessibility, while driving down costs. More importantly, innovation should change the way the world works and lead to a more sustainable future.

Disruptive Innovation Is Key To Growth

ARK is a global asset manager specializing in thematic investing in disruptive innovation. The firm is rooted in over 40 years of experience in investing in technologies that aim to deliver outsized growth as industries transform.

Through its open research process, ARK seeks to identify companies that are leading and benefiting from cross-sector innovations such as artificial intelligence, robotics, energy storage, DNA sequencing, and blockchain technology.

Innovation Research

• White Papers
• Newsletters

ARK’s Investment Process

Top-down research.

To define the investment universe, ARK’s investment process initially examines how the world is changing and where it is headed.

Identify Disruptive Innovation

Sizing The Opportunity

Define The Potential Universe

Bottom-Up Research

To refine the investment opportunity, ARK’s bottom-up analysis evaluates potential investments based on our defined key metrics.

Stock Selection And Valuation

Select Portfolio Companies

Portfolio And Risk Management

Monitor Conviction & Market Volatility

Receive Regular Updates And Notifications On ARK’s Latest Research Because Investing In Innovation Starts With Understanding It

Cars for sale

Sell my car, car research, sign in, what is nissan safety shield.

Nissan's six-feature safety suite uses cameras, radars, and sonar for 360-degree protection.

QuickTakes:

• Nissan Safety Shield 360 includes driver-assistance and crash-avoidance tech
• Most Nissan vehicles have Nissan Safety Shield
• Nissan offers more safety features

Nissan USA says it offers all-around protection on its vehicles, and it accomplishes this with a suite of safety products Nissan Safety Shield 360. The six-feature system is robust with uplevel features you often only see in luxury vehicles.

Nissan Safety Shield 360 Includes Driver-Assistance and Crash-Avoidance Tech

Using cameras, radar, and sonar technology, Nissan Safety Shield 360 offers six advanced features that monitor the areas surrounding the vehicle. It can either alert the driver to potential problems or actively intervene in a potential crash situation.

The first feature, automatic emergency braking , is standard on 90% of all light-duty vehicles currently on the road. The system provides both audio and visual alerts if it detects a possible collision with another vehicle or pedestrian. It can also apply the brakes.

The second and third features are also frequently included on standard safety suites in most daily drivers. These are high-beam assist, which turns down your high-beams when it senses oncoming traffic, and lane-departure warning, which issues an alert if it detects the vehicle is leaving its lane.

Three more features are more on the premium side of the spectrum and include blind-spot monitoring , rear cross-traffic alert , and automatic rear braking. The first two features will issue visual and audible alerts as another vehicle enters your blind spots, and the latter feature will apply the brakes if it detects an object behind the vehicle and the driver fails to stop in time to prevent a collision.

Most Nissan Vehicles Have Nissan Safety Shield

Nissan includes Safety Shield 360 on almost every vehicle it builds, from the compact Versa SV at about $21,000 to the full-size Armada SUV at about $52,000. This includes both of its pickup trucks, the Frontier and the Titan.

The only vehicles that do not come with Safety Shield 360 include the two most basic Versas in the S trim, with both manual and automatic transmissions, as well as the GT-R. Since Nissan Safety Shield 360 is standard on all the vehicles that have it, there is no additional cost.

Nissan Offers More Safety Features

In addition to Nissan Safety Shield 360, there are two other notable safety features available on Nissan vehicles. The first is a 360-degree monitor that Nissan calls the Around View Monitor.

This includes a four-camera system that gives both a rear view and a bird's-eye view of the vehicle. This will help drivers see all the obstacles they might encounter when moving the vehicle forward or backward. While the Around View Monitor isn't available on the Versa, it is offered on every other Nissan model.

The second available safety feature is ProPilot Assist , which is a hands-on driver assist system that combines adaptive cruise control and lane-keeping assist to help modulate the vehicle's speed. This helps keep the vehicle a safe distance from the one in front of it as well as ensuring that the vehicle stays within its lane lines.

This feature is available in the Altima , Leaf , Rogue Sport, Rogue , and Pathfinder . Nissan also offers a 2.0 version of ProPilot Assist in the Ariya that is a hands-free highway driver-assist system. While the 2.0 system won't allow the vehicle to change lanes hands free, it will use steering assist to help guide drivers into a new lane as long as they have their hands lightly on the wheel.

All vehicle pricing includes MSRP plus destination charges (set at the time of publication), and will be rounded to the nearest thousand.

Written by humans. Edited by humans.

Jill Ciminillo is a Chicago-based automotive writer, YouTube personality, and podcast host, with her articles and videos appearing in outlets throughout the U.S. Additionally, she co-hosts a weekly radio show on cars for a local Chicago station. Previously, Jill has been the automotive editor for both newspaper and broadcast media conglomerates. She is also a past president for the Midwest Automotive Media Association and has the distinction of being the first female president for that organization.

Related articles

View more related articles

Evidence-Based Investing

In healthcare & life sciences.

Artist: Luke Jerram | Title: Ebola

RA Capital Management is a Multi-Stage Investment Manager

We are dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools.

Venture Investing

We can work with you to build a company that brings your idea from the lab into the clinic and ultimately improves the lives of patients.

Research at RA Capital

TechAtlas is a division of RA Capital that functions as an internal think tank, analyzing scientific and clinical data from academic literature and thousands of industry product development programs.

Many Backgrounds. Different Perspectives. Persistently Curious.

CHRIS BROWN, PhD

HANNAH O'LEARY

Executive Assistant

EMILY ENGEL

Senior Manager, Clinical Operations

YASH CHALASANI, MD

TESS CAMERON

JACQUELINE RHUDA

Senior Associate, Strategic Finance

Chris Brown is an Associate within the Planetary Health division at RA Capital Management. His primary responsibility is to create detailed competitive landscapes of planetary health solutions. Prior to RA, Chris worked as a post-doc in the Johnson group at MIT, and he has eight first-author publications in research that spans degradable polymers, energy-efficient catalysis, and low-energy lighting devices. Chris has a Master of Chemistry in Organic Chemistry from Newcastle University and a PhD in Inorganic Chemistry from the University of British Columbia.

Hannah O'Leary is an Executive Assistant at RA Capital Management. Hannah’s primary responsibilities are to coordinate calendars, events, and company meetings for the Marketing and External Affairs Team. Hannah previously held posts as Coordinator to the President at the National Collegiate Athletic Association (NCAA), Marketing Lead and Project Manager at Bose Corporation, Event Services Manager at the Massachusetts Convention Center Authority, and Events Coordinator for Governor Charlie Baker’s Re-Election Campaign. She has a BS in Communication with an emphasis in Public Relations and a minor in American Studies from Boston University.

Emily Engel is a Senior Manager, Clinical Operations at RA Ventures (RAVen). Emily's primary responsibilities at RAVen are to support Clinical Operations and Patient Engagement efforts to identify and implement best practices in clinical trial operations in RA's newco's and portfolio companies. Emily was previously the Global Clinical Trial Manager at Amylyx where she managed Phase I-III clinical trials as well as Expanded Access Programs, providing new therapies for rare, neurodegenerative disorders at no cost to participants, including RELYVRIO®/ALBRIOZA™ for the treatment of Amyotrophic Lateral Sclerosis. Before Amylyx, she was the Clinical Project Manager at Eledon Pharmaceuticals where she managed a team overseeing the operations of several early-stage clinical programs including kidney and islet cell transplantation. She has prior project management and clinical trial experience at IQVIA. Massachusetts General Hospital and Dana-Farber Cancer Institute. Emily has a BS in Public Health Services from the University of Massachusetts - Amherst.

Yash Chalasani is an Associate with the TechAtlas division of RA Capital. Yash works closely with the investment team to understand competitive landscapes, evaluate investment opportunities, and advise portfolio companies on program and pipeline strategy. Prior to RA, Yash held various roles at Eventide Asset Management, Reata Pharmaceuticals, and Bios Partners. Yash has a BBA in Finance from Baylor University and an MD from Baylor College of Medicine.

Tess Cameron is a Principal on the Investment Team at RA Capital Management. Tess works on both public and private investments and serves on several company boards. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada.

Jacqueline is a Senior Associate, Strategic Finance at RA Capital Management. Jacqueline’s primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. While at Johns Hopkins, she spent two years as a Research Intern and Teaching Assistant in the Department of Biology and the Department of Chemistry.

Join Our Team

We welcome inquiries from people interested in joining the RA Capital team. From time to time we may post specific open positions, but more often we will create positions for the right people.

Knowledge Overview

Articles, presentations, and books with our insights into biotech, healthcare, and investing.

RA University

Short, intensive courses on a variety of advanced topics relevant to the business of biotechnology at no cost to admitted participants.

We originate conviction. We do not borrow it from others.

We expect and strive to inspire the best in everyone.

We embrace the unfamiliar.

We do not let convention stand in the way of what is right.

We learn collaboratively.

We have a bias for action.

We are persistently curious and humbled by what is left to learn.

We are data-driven and challenge assumptions.

We preserve the ability to change our mind.

We admit our mistakes and share lessons learned.

We address the elephant in the room.

We value our relationships and are positive, respectful, and open-minded.

We take fun seriously.

Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. By continuing, you accept the use of these cookies.

• Search Search Please fill out this field.
• Business Essentials

Return on Research Capital (RORC): What it is, How it Works

What Is Return on Research Capital?

Return on research capital (RORC) is a calculation used to assess the revenue a company brings in as a result of expenditures made on research and development (R&D) activities.

Return on research capital is a component of productivity and growth since research and development is one of the ways companies develop new products and services for sale. This metric is commonly used in industries that rely heavily on R&D, such as the pharmaceutical industry .

Key Takeaways

• Return on research capital (RORC) measures a firm's revenues generated from R&D activities.
• Return on research capital (RORC) is calculated by dividing current gross profits by the prior year's R&D expenditures.
• It usually takes more than one year to realize the return on R&D; sometimes, it may be realized over more than one year.

Understanding Return on Research Capital (RORC)

Companies face an opportunity cost when examining the use of their funds. They can spend money on tangible assets, real estate, capital improvements , or they can invest in R&D. Investments made in research may take many years before tangible results are realized, and the return typically varies between industries and even within sectors of a particular industry.

In theory, if an enterprise has promising prospects, it should forgo returning capital and plow back retained earnings into the business. Investing in research and development is one popular method to develop future innovation capabilities. Analysts and investors monitor R&D levels to gauge future competitiveness. Many industries have come under fire for shrinking R&D budgets, while stock buybacks are at all-time highs.

Research and development initiatives are very difficult to manage since the defining feature of the research is that the researchers do not know in advance exactly how to accomplish any given desired result. In larger businesses, monitoring R&D spending presents a problem. As a result, higher R&D spending does not guarantee more creativity, higher profits, or more market share. Thus, at times, managers struggle to effectively prove the return on research capital.

Recent breakthroughs in big data, analytics, and enterprise risk management methodologies help demonstrate, with evidence-based proof, that investment in research and development adds enterprise value. In business, money follows success. As business leaders further demonstrate return on research efforts, budgets will grow as well.

Large and complex research and development projects may not produce profits for years after completion, rendering this analysis faulty.

Example of Return on Research Capital

The return on research capital is the amount of profit earned for each dollar spent on research and development within a given period (usually a year). It is calculated as current gross profits (typically found on the current year's income statement) divided by the prior year's R&D expenses.

The prior year's R&D expenses are used because the payoff is not typically realized immediately. Rather, it is often realized at some future point in time. For example, Rx Pharmaceutical Company earned $100 million in gross profits in 2021. In the previous year, it spent $50 million on research and development. It's return on research capital is $2 ($100 million / $50 million). So for every $1 spent on research and development, the company earned $2 in gross profit. One can reasonably assume that higher returns mean that the company has spent wisely in terms of research and development and is reaping the rewards from its efforts.

What Is Return on Research Capital (RORC) Used For?

Return on research capital (RORC) is a measure of what revenue a corporation has earned as a result of it having spent money on research and development (R&D). The metric is used to assess the effectiveness of R&D. 

What Is the Price-to-Research Ratio (PRR)?

The price-to-research ratio (PRR) measures the connection between a company's market capitalization and its research and development (R&D) spending. It can be used to compare different companies' R&D spending. It is calculated by dividing a company's market capitalization by what it spent on R&D over the previous 12 months. A PRR between five and ten is a preferred number, as it suggests a company is redirecting current profits into research and development, which should positively impact long-term future returns. 

What Sectors' Profits Are Most Influenced By R&D Spending?

Many sectors and corporations benefit from spending on research & development, but technology and pharmaceuticals are among the industries that benefit the most. Pharmaceuticals. in particular, are dependent on research and development in the creation, testing, and manufacturing of drugs and other medicines.

• Terms of Service
• Editorial Policy
• Privacy Policy

Navigation Menu

Search code, repositories, users, issues, pull requests..., provide feedback.

We read every piece of feedback, and take your input very seriously.

Saved searches

Use saved searches to filter your results more quickly.

To see all available qualifiers, see our documentation .

A&R Research Capital

Pinned loading.

exchange-link

Repositories

This organization has no public members. You must be a member to see who’s a part of this organization.

Top languages

Most used topics.

• Quick Facts
• Sights & Attractions
• Tsarskoe Selo
• Oranienbaum
• Foreign St. Petersburg
• Restaurants & Bars
• Accommodation Guide
• St. Petersburg Hotels
• Serviced Apartments
• Bed and Breakfasts
• Private & Group Transfers
• Airport Transfers
• Concierge Service
• Russian Visa Guide
• Request Visa Support
• Walking Tours
• River Entertainment
• Public Transportation
• Travel Cards
• Essential Shopping Selection
• Business Directory
• Photo Gallery
• Video Gallery
• 360° Panoramas
• Moscow Hotels
• Moscow.Info
• Religious Sights

Orthodox Cathedrals

St. Petersburg's Orthodox Cathedrals include some of the most magnificent churches in Russia. Built at the height of the Russian Empire's wealth and power, when the capital's churches were as important as palaces to show the eminence and prestige of Russia's rulers, these impressive buildings were designed by the city's greatest architects, and no expense was spared in their construction or decoration.

We can help you make the right choice from hundreds of St. Petersburg hotels and hostels.

Live like a local in self-catering apartments at convenient locations in St. Petersburg.

Comprehensive solutions for those who relocate to St. Petersburg to live, work or study.

Maximize your time in St. Petersburg with tours expertly tailored to your interests.

Get around in comfort with a chauffeured car or van to suit your budget and requirements.

Book a comfortable, well-maintained bus or a van with professional driver for your group.

Navigate St. Petersburg’s dining scene and find restaurants to remember.

Need tickets for the Mariinsky, the Hermitage, a football game or any event? We can help.

Get our help and advice choosing services and options to plan a prefect train journey.

Let our meeting and events experts help you organize a superb event in St. Petersburg.

We can find you a suitable interpreter for your negotiations, research or other needs.

Get translations for all purposes from recommended professional translators.

We are online 24/7

We Optimize and Grow Your Business

For Your Growth

Discover New Horizons in Business

Startups in the creative industries, overview of a & r capital private limited.

• MARKET RESEARCH
• BUSINESS STRATEGY

Cooperation with you

Real words, with thoughts that count, information that has value slice when you.

Growing your business

The paint you may slap on your face to impress the new boss is your business.

Safe your time

Authorities in our business will tell in no uncertain terms that Lorem Ipsum is that.

Explore Our Offerings

Personal Loans

Instant personal loans to fulfil any need

Business Loans

Unsecured business loans upto INR 1 Lakhs*

GOLD AND PROPERTY LOAN

Competitive Gold loans up to INR 5 Lacs

How Effective Is What Our Clients Use?

Check out these rules.

That’s not so bad, there’s dummy copy to the rescue. But worse, what if the fish doesn’t fit in the can, the foot’s to big for the boot? Or to small? To short sentences, to many headings, images too large for the proposed design, or too small.

A client that’s unhappy for a reason is a problem, a client that’s unhappy though he or her can’t quite put a finger on it is worse. Or they fit in but it looks iffy for reasons the folks in the meeting can’t quite tell right now, but they’re unhappy, somehow.

Working Days of Our Company

A small river named Duden flows by their place and supplies it with the necessary regelialia. It is a paradisematic country, in which roasted.

Trusted Us for A Long Time!

How much do trust us.

A small river named Duden flows by their place and supplies it with the necessary.

Cooperation with The Client

She packed her seven versalia, put her initial into the belt and made herself.

Be Aware of All Events

Blog Post Title

Exploring Atlanta’s modern homes

Green interior design inspiration

Collar brings back coffee brewing ritual

Get Answers to All Your Questions You Might Have

Get free consultation.

We are ready to answer right now! Sign up for a free consultation.

I consent to the processing of personal data and agree with the user agreement and privacy policy

• Login / Register